Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Eric David Miller

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4931-3521; OpenAlex author ID A5043067705. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 9

  1. Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/s12029-026-01600-0↗
  2. Innovative Targets, New Technologies, Same Tenacity: Radiation Therapy's Evolving Role in Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2025.11.058↗
  3. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  4. Intraoperative Radiation for Pancreatic Cancer. Last author DOI 10.1016/j.semradonc.2025.07.008↗
  5. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  6. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  7. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
  8. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Co-author DOI 10.1016/j.radonc.2021.02.035↗
  9. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 6 shared papers, 2020–2025 · strength 0.98
  2. Aslam M. Ejaz · 5 shared papers, 2021–2026 · strength 0.97
  3. Mary E. Dillhoff · 5 shared papers, 2020–2025 · strength 0.83
  4. Anne M. Noonan · 4 shared papers, 2020–2025 · strength 0.62
  5. Ashish Manne · 3 shared papers, 2024–2025 · strength 0.61
  6. Timothy Michael Pawlik · 3 shared papers, 2022–2025 · strength 0.60
  7. Patrick W. Underwood · 2 shared papers, 2025 · strength 0.45
  8. Somashekar Gopala Krishna · 2 shared papers, 2022–2025 · strength 0.38
  9. Kenneth L Pitter · 2 shared papers, 2024–2025 · strength 0.37
  10. Shafia Rahman · 2 shared papers, 2024–2025 · strength 0.37
  11. Ahmed Elguindy · 1 shared paper, 2025 · strength 0.37
  12. Bradley Norman Reames · 1 shared paper, 2026 · strength 0.32
  13. Michael David Chuong · 1 shared paper, 2026 · strength 0.32
  14. Ziyi Zhou · 1 shared paper, 2026 · strength 0.32
  15. Luca Boldrini · 1 shared paper, 2026 · strength 0.32
  16. Patrick L. Quinn · 1 shared paper, 2026 · strength 0.32
  17. Krishan R. Jethwa · 1 shared paper, 2026 · strength 0.32
  18. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.32
  19. Allan Tsung · 2 shared papers, 2021–2022 · strength 0.27
  20. Syed Ameen Ahmad · 1 shared paper, 2025 · strength 0.24
  21. Adam R. Wolfe · 2 shared papers, 2020–2021 · strength 0.22
  22. Terence Marques Williams · 2 shared papers, 2020–2021 · strength 0.22
  23. Sameek Roychowdhury · 1 shared paper, 2024 · strength 0.15
  24. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.15
  25. Upender Manne Manne · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.